|
|
|
|
LEADER |
01000naa a22002652 4500 |
001 |
NLM216088321 |
003 |
DE-627 |
005 |
20231224030942.0 |
007 |
cr uuu---uuuuu |
008 |
231224s2012 xx |||||o 00| ||eng c |
024 |
7 |
|
|a 10.1016/j.clim.2012.02.002
|2 doi
|
028 |
5 |
2 |
|a pubmed24n0720.xml
|
035 |
|
|
|a (DE-627)NLM216088321
|
035 |
|
|
|a (NLM)22406048
|
040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
041 |
|
|
|a eng
|
100 |
1 |
|
|a Zhao, Ming
|e verfasserin
|4 aut
|
245 |
1 |
0 |
|a Total glucosides of paeony induces regulatory CD4(+)CD25(+) T cells by increasing Foxp3 demethylation in lupus CD4(+) T cells
|
264 |
|
1 |
|c 2012
|
336 |
|
|
|a Text
|b txt
|2 rdacontent
|
337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
500 |
|
|
|a Date Completed 29.05.2012
|
500 |
|
|
|a Date Revised 17.03.2022
|
500 |
|
|
|a published: Print-Electronic
|
500 |
|
|
|a Citation Status MEDLINE
|
520 |
|
|
|a Copyright © 2012 Elsevier Inc. All rights reserved.
|
520 |
|
|
|a Total glucosides of paeony (TGP), an active compound extracted from Paeony root, has been used in therapy for autoimmune diseases. However the molecular mechanism of TGP in the prevention of autoimmune response remains unclear. In this study, we found that TGP treatment significantly increased the percentage and number of Treg cells in lupus CD4(+) T cells. Further investigation revealed that treatment with TGP increased the expression of Foxp3 in lupus CD4(+) T cells by down-regulating Foxp3 promoter methylation levels. However, we couldn't observe similar results in healthy control CD4(+) T cells treated by TGP. Moreover, our results also showed that IFN-γ and IL-2 expression was enhanced in TGP-treated lupus CD4(+) T cells. These findings indicate that TGP inhibits autoimmunity in SLE patients possibly by inducing Treg cell differentiation, which may in turn be due to its ability to regulate the methylation status of the Foxp3 promoter and activate IFN-γ and IL-2 signaling
|
650 |
|
4 |
|a Journal Article
|
650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
650 |
|
7 |
|a Cytokines
|2 NLM
|
650 |
|
7 |
|a FOXP3 protein, human
|2 NLM
|
650 |
|
7 |
|a Forkhead Transcription Factors
|2 NLM
|
650 |
|
7 |
|a Glucosides
|2 NLM
|
650 |
|
7 |
|a Interleukin-2 Receptor alpha Subunit
|2 NLM
|
650 |
|
7 |
|a RNA, Messenger
|2 NLM
|
700 |
1 |
|
|a Liang, Gong-ping
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Tang, Mei-ni
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Luo, Shuang-yan
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Zhang, Jing
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Cheng, Wen-jing
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Chan, Tak-mao
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Lu, Qian-jin
|e verfasserin
|4 aut
|
773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 143(2012), 2 vom: 07. Mai, Seite 180-7
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
773 |
1 |
8 |
|g volume:143
|g year:2012
|g number:2
|g day:07
|g month:05
|g pages:180-7
|
856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2012.02.002
|3 Volltext
|
912 |
|
|
|a GBV_USEFLAG_A
|
912 |
|
|
|a SYSFLAG_A
|
912 |
|
|
|a GBV_NLM
|
912 |
|
|
|a GBV_ILN_11
|
912 |
|
|
|a GBV_ILN_24
|
912 |
|
|
|a GBV_ILN_350
|
951 |
|
|
|a AR
|
952 |
|
|
|d 143
|j 2012
|e 2
|b 07
|c 05
|h 180-7
|